Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4SigHT: Long-term effectiveness and safety of Uplizna (inebilizumab) in IgG4-related disease in Japan
jRCT1031250749Recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of inebilizumab in IgG4-related disease (IgG4-RD), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Proportion of participants with adjudicated clinical flare of IgG4-RD at Week 52. Started Mar 2026; status: recruiting.
02
Drugs
inebilizumab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on jRCT1031250749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250749.